Prelude Therapeutics Inc

NASDAQ:PRLDUnited States

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Contact Information

Headquarters

175 Innovation BoulevardWILMINGTON, DE, United States 19805

Phone

302-467-1280

Fax

302-658-3989

Executives

Independent Chairman of the Board

Paul Friedman

President, Chief Medical Officer

Jane Huang

Chief Executive Officer, Founder, Director

Krishna Vaddi

Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary

Bryant Lim

Executive Vice President, Head of Chemistry

Andrew Combs